Stock Movers Novo Nordisk Rises, GoodRX Surges, CVS Gains on UBS Upgrade
Aug 18, 2025
Novo Nordisk announces a significant price cut for Ozempic, benefiting cash-paying patients and teaming up with GoodRx to streamline access. This collaboration boosts GoodRx's stock as demand surges. Meanwhile, CVS sees a rise in shares following a favorable UBS upgrade, signaling strong performance and future potential in its Healthcare Benefits segment. The interplay of drug pricing and market strategy makes for an engaging discussion.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Lowers Ozempic Price
- Novo Nordisk cut Ozempic cash price to $499/month to reach uninsured patients and ease political pressure on drug pricing.
- The move coincides with other product news and follows public scrutiny of pharma pricing strategies.
GoodRx Gains From Novo Nordisk Deal
- GoodRx stands to monetize GLP-1 demand by partnering with Novo Nordisk to offer Ozempic at pharmacies.
- Analysts estimate the deal could reach roughly 17 million patients seeking these drugs.
CVS Upgrade Reflects Business Turnaround
- UBS upgraded CVS after back-to-back strong quarters and signs of fixes in its Healthcare Benefits segment.
- CVS is refocusing away from ACA exchanges toward higher-margin segments like Medicare Advantage.